Full Schedule

08:00 – 09:25 CEST

Session XI: Presentation of Selected Abstracts: Colorectal Cancer

Chair: – Università degli Studi della Campania Luigi Vanvitelli

Chair: – Instituto Alexander Fleming

08:00 – 08:08 CEST

SO-17: A new risk classification integrating ctDNA, CEA and pTN stage for DFS prognosis and predictive value for treatment duration in stage III colon cancer

Abstract Presenter:

08:08 – 08:16 CEST

SO-18: ctDNA-guided adjuvant treatment after radical intent treatment of metastatic spread from colorectal cancer is feasible – results from the preplanned interim analysis of the OPTIMISE Study

Abstract Presenter:

08:16 – 08:24 CEST

SO-19: The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A national cancer database analysis

Abstract Presenter:

08:24 – 08:34 CEST

Discussant: SO-17, SO-18, SO-19

Discussant: – Odense University Hospital

08:34 – 08:44 CEST

O-8: Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection

Abstract Presenter:

08:44 – 08:52 CEST

SO-20: The landscape Of homologous recombination deficiency in colorectal cancer

Abstract Presenter:

08:52 – 09:00 CEST

SO-21: Tumor mutational signatures in early-onset versus average-onset colorectal cancer

Abstract Presenter:

09:00 – 09:08 CEST

SO-34: Multi-label transcriptional classification of colorectal cancer reflects tumour cell population heterogeneity

Abstract Presenter:

09:08 – 09:25 CEST

Discussant: O-8, SO-20, SO-21, SO-34

Discussant: – Université Paris Cité

08:00 – 09:25 CEST

Session XII: Minisymposium: The Role of Functional Imaging in GI Cancer

Chair: – University Hospitals Leuven / KU Leuven

Chair: – Masaryk Memorial Cancer Institute and Masaryk University

08:00 – 08:20 CEST

Intriguing Cases on Imaging

Panelist: – University Hospitals Leuven / KU Leuven

Panelist: – Vall d'Hebron Institute of Oncology

08:20 – 08:40 CEST

PET/CT

Speaker: – University Hospitals Leuven / KU Leuven

08:40 – 09:00 CEST

Radiomics in GI Cancer

Speaker: – Vall d'Hebron Institute of Oncology

09:00 – 09:25 CEST

Q&A and Panel Discussion

Moderator: – University Hospitals Leuven / KU Leuven

Moderator: – Masaryk Memorial Cancer Institute and Masaryk University

Panelist: – Vall d'Hebron Institute of Oncology

08:00 – 09:25 CEST

Session XIII: GI Cancer in Elderly: Challenges and Prospects (includes IO in elderly)

Chair: – Vanderbilt-Ingram Cancer Center

Chair: – Bank of Cyprus Oncology Centre

08:00 – 08:15 CEST

Geriatric Factors and Outcomes

Speaker: – Bank of Cyprus Oncology Centre

08:15 – 08:35 CEST

Management of Upper GI Cancers in the Elderly

Speaker: – Klinikum rechts der Isar, Technical University Munich

08:35 – 08:55 CEST

Management of Colorectal Cancer in the Elderly – Adjuvant Therapy

Speaker: – Institut Paoli-Calmettes

08:55 – 09:15 CEST

Immunotherapy for GI Cancers in the Elderly

Speaker: – The Royal Marsden Hospital

09:15 – 09:25 CEST

Q&A and Panel Discussion

Moderator: – Vanderbilt-Ingram Cancer Center

Moderator: – Bank of Cyprus Oncology Centre

Panelist: – Institut Paoli-Calmettes

Panelist: – Klinikum rechts der Isar, Technical University Munich

Panelist: – The Royal Marsden Hospital

08:00 – 09:25 CEST

Session XIV: WCGIC: Molecular Marker Platforms: Focus on Liquid Biopsies

Chair: – Université Paris Cité

Chair: – Hospital del Mar

Chair: – Vall d’Hebron University Hospital

08:00 – 09:25 CEST

Precision Medicine Development in Gastrointestinal Oncology: Evidence-Based Guidelines Using Liquid Biopsies in Treatment, Decision Making, Optimizing Management, and Sequencing

Panelist: – Peter MacCallum Cancer Centre

Panelist: – Institut Paoli-Calmettes

Panelist: – Fondazione IRCCS Istituto Nazionale dei Tumori

Panelist: – Asklepios Tumorzentrum Hamburg

09:30 – 10:30 CEST

Session XV: Emerging Targets in GI Cancer

Chair: – Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP)

Chair: – University Hospitals Leuven / KU Leuven

09:30 – 09:50 CEST

Targeting RAS Mutations

Speaker: – Duke University

09:50 – 10:10 CEST

Targeting the HER2 Pathway in GI Cancer

Speaker: – Hospital Clínico Valencia

10:10 – 10:30 CEST

Targeting Claudin 18.2 in GI Cancer

Speaker: – Masaryk Memorial Cancer Institute and Masaryk University

10:30 – 11:00 CEST

Break and Poster Viewing

10:35 – 10:55 CEST

Poster Discussion Guided Tours - Group 7: Colon Cancer I (PD-18, PD-19, PD-20)

Poster Discussant: – Università degli Studi della Campania Luigi Vanvitelli

10:35 – 10:55 CEST

Poster Discussion Guided Tours - Group 8: Colon Cancer II (PD-21, PD-22, PD-23, PD-24)

Poster Discussant: – Université Paris Cité

11:00 – 13:15 CEST

Session XVI: Rectal Cancer

Chair: – University Hospitals Leuven / KU Leuven

Chair: – Università degli Studi della Campania Luigi Vanvitelli

11:00 – 11:20 CEST

MRI: New Data and Learnings in Rectal Cancer

Speaker: – Imperial College

11:20 – 11:28 CEST

A Critical Reappraisal of an Optimal TNT Strategy by an MDT: A Surgeon’s Viewpoint

Speaker: – University Hospitals Leuven / KU Leuven

11:28 – 11:36 CEST

A Critical Reappraisal of an Optimal TNT Strategy by an MDT: A Medical Oncologist’s Viewpoint

Speaker: – University Hospitals Leuven / KU Leuven

11:36 – 11:44 CEST

A Critical Reappraisal of an Optimal TNT Strategy by an MDT: A Radiation Oncologist’s Viewpoint

Speaker: – University Hospitals Leuven / KU Leuven

11:44 – 11:55 CEST

A Critical Reappraisal of an Optimal TNT Strategy by an MDT: Q&A and Panel Discussion

Moderator: – University Hospitals Leuven / KU Leuven

Moderator: – Università degli Studi della Campania Luigi Vanvitelli

Panelist: – University Hospitals Leuven / KU Leuven

Panelist: – Hôpital Tenon, AP-HP, Sorbonne Université

Panelist: – Hospital Alemão Oswaldo Cruz

Panelist: – Maria Sklodowska-Curie National Cancer Research Institute

11:55 – 12:10 CEST

Surveillance in Non-Operative Management/Watch & Wait Strategy: How to do?

Speaker: – Hospital Alemão Oswaldo Cruz

12:10 – 12:30 CEST

Flash: How to Integrate CPI in MSI-H Rectal Cancer: Double CPI? Duration? Role of RT?

Speaker: – Hopital Saint Antoine

12:20 – 12:30 CEST

Flash: Is Robotic Surgery Taking off in Rectal Cancer

Speaker: – University of Portsmouth, Portsmouth Hospitals University NHS Trust

12:30 – 12:45 CEST

The Challenge of Lateral Lymph Nodes

Speaker: – MD Anderson Cancer Center, The University of Texas

12:45 – 13:15 CEST

Challenging Cases in Rectal Cancer

Moderator: – University Hospitals Leuven / KU Leuven

Moderator: – Università degli Studi della Campania Luigi Vanvitelli

Panelist: – Rambam Health Care Campus

Panelist: – MD Anderson Cancer Center, The University of Texas

Panelist: – Hôpital Tenon, AP-HP, Sorbonne Université

Panelist: – Hospital Alemão Oswaldo Cruz

13:15 – 13:30 CEST

Break

13:30 – 15:00 CEST

Lunch Symposium: In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/ Gastroesophageal Junction Cancer Supported by Daiichi Sankyo

13:30 – 15:00 CEST

Lunch Symposium: New Hope for Metastatic Pancreatic Cancer Patients Supported by Servier International Medical Affairs

13:30 – 15:00 CEST

Lunch Symposium: Putting the Pieces Together to Optimise the Management of BRAF V600E-mutant mCRC Supported by Pierre Fabre

13:30 – 15:00 CEST

Lunch Symposium: Value of Disease Stabilization Across GI Tumors Supported by Bayer

15:15 – 16:40 CEST

Session XVII: Adjuvant and Neoadjuvant Treatment of Colon Cancer

Chair: – Lombardi Comprehensive Cancer Center, Georgetown University

Chair: – University Hospitals Leuven / KU Leuven

15:40 – 15:50 CEST

Debate: Are We Ready to Integrate ctDNA in Treatment Selection - YES

Debate Speaker: – Peter MacCallum Cancer Centre

15:45 – 15:55 CEST

Debate: Neoadjuvant Therapy in Locally Advanced Colon Cancer - YES

Debate Speaker: – University of Leeds

15:50 – 16:00 CEST

Debate: Are We Ready to Integrate ctDNA in Treatment Selection - NO

Debate Speaker: – Vall Hebron University Hospital

15:55 – 16:05 CEST

Debate: Neoadjuvant Therapy in Locally Advanced Colon Cancer - NO

Debate Speaker: – Hopital Saint Antoine

16:00 – 16:10 CEST

Debate: Are We Ready to Integrate ctDNA in Treatment Selection - DISCUSSION

Panelist: – Peter MacCallum Cancer Centre

Panelist: – Vall Hebron University Hospital

16:05 – 16:15 CEST

Debate: Neoadjuvant Therapy in Locally Advanced Colon Cancer - DISCUSSION

Panelist: – University of Leeds

Panelist: – Hopital Saint Antoine

16:15 – 16:40 CEST

Keynote Lecture: Single Cell Analysis and Transcriptomics

Keynote Speaker: – University Hospitals Leuven / KU Leuven

16:45 – 17:15 CEST

Break and Poster Viewing

16:50 – 17:10 CEST

Poster Discussion Guided Tours - Group 10: Colorectal and Anal Cancers (PD-27, PD-28, PD-29)

Poster Discussant: – Vanderbilt-Ingram Cancer Center

16:50 – 17:10 CEST

Poster Discussion Guided Tours - Group 9: Colorectal Cancer III (PD-25, PD-26)

Poster Discussant: – Medical Oncology Department, Oncology Institute of Southern Switzerland

16:45 – 17:30 CEST

ESMO Lounge Session: Complex Clinical Trials in GI Cancers: Is the Pain Worth the Gain?

Session Chair: – Hacettepe University Cancer Institute

Session Chair: – St Bart's Hospital

Speaker: – University of Leeds

17:15 – 18:30 CEST

Session XVIII: Immune Mechanisms and Microbiome in GI Tumors

Chair: – Medical Oncology Department, Oncology Institute of Southern Switzerland

Chair: – Vall d’Hebron University Hospital

17:15 – 17:23 CEST

SO-22: Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the AtezoTRIBE study

Abstract Presenter:

17:23 – 17:31 CEST

SO-23: The influence of the microbiome on the tumour-immune microenvironment in colorectal cancer

Abstract Presenter:

17:31 – 18:00 CEST

Microbiome and Colorectal Cancer

Speaker: – Vall Hebron University Hospital

18:00 – 18:10 CEST

LBA-4: Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

Abstract Presenter:

18:10 – 18:30 CEST

Resistance Factors to IOs

Speaker: – Memorial Sloan Kettering Cancer Center

18:30 – 19:15 CEST

Session XIX: Predicting and Managing Rare Toxicities in Patients With GI Cancers

Chair: – King Faisal Specialist Hospital and Research Center-Riyadh

Chair: – Vall Hebron University Hospital

Chair: – Bank of Cyprus Oncology Centre

18:30 – 18:40 CEST

O-9: Health‑related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial

Abstract Presenter: – Medizinische Universität Wien

18:30 – 18:50 CEST

O-10: Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C)

Abstract Presenter: – Universitätsmedizin Mainz

18:50 – 19:15 CEST

Keynote Lecture: Toxicity Management - Nausea and Vomiting

Speaker: – Clinique de Genolier